1-isopropyl-1-N-methylpropylamino-(3,4-dimethoxyphenyl)acetonitrile,
2-(3,4-dimethoxyphenyl)-5-amino-2-isopropylvaleronitrile,
2-(3,4-dimethoxyphenyl)-5-amino-2-isopropylvaleronitrile hydrochloride,
D 617,
D-617,
34245-14-2,
rac D 617 (Verapamil Metabolite),
CHEMBL1743342,
CHEBI:83528,
WLOBUUJURNEQCL-UHFFFAOYSA-N,
2-(3,4-dimethoxyphenyl)-5-amino-2-isopropylvaleronitrile,
D617,
2-(3,4-dimethoxyphenyl)-5-methylamino-2-isopropylvaleronitrile,
2-(3,4-Dimethoxyphenyl)-2-isopropyl-5-(methylamino)pentanenitrile,
D-617,
3-(3,4-Dimethoxyphenyl)-2-methyl-6-methylaminohexane-3-carbonitrile,
n-methyl-4-(3,4-dimethoxyphenyl)-4-cyano-5-methylhexylamine,
2-(3,4-dimethoxyphenyl)-5-(methylamino)-2-propan-2-ylpentanenitrile,
2-(3,4-dimethoxyphenyl)-5-(methylamino)-2-(propan-2-yl)pentanenitrile,
3,4-Dimethoxy-alpha-(3-(methylamino)propyl)-alpha-(1-methylethyl)benzeneacetonitrile,
Benzeneacetonitrile,3,4-dimethoxy-a-[3-(methylamino)propyl]-a-(1-methylethyl)-,
RAC D 617 (N-METHYL-4-(3,4-DIMETHOXYPHENYL)-4-CYANO-5-METHYLHEXYLAMINE),
EINECS 251-895-1,
Verapamil Impurity F,
AC1L3PN7,
AC1Q4QM7,
Verapamil metabolite D-617,
SCHEMBL6387741,
CTK4H1987,
BDBM50418097,
AKOS030255337,
FT-0665436,
A822789,
J-019519,
4-cyano-4-(3,4-dimethoxyphenyl)-5,N-dimethyl-hexylamine,
5-Methylamino-2-(3,4-dimethoxyphenyl-2-isopropylvaleronitrile,
1-Isopropyl-1-N-methylpropylamino-(3,4-dimethoxyphenyl)acetonitrile,
2-(3',4'-dimethoxyphenyl)-2-isopropyl-5-methylamino pentanenitrile,
2-(3',4'-dimethoxyphenyl)-2-isopropyl-5-methylaminopentanenitrile,
2-(3,4-Dimethoxyphenyl)-2-isopropyl-5-(methylamino)valeronitrile,
2-(3,4-Dimethoxyphenyl)-2-isopropyl-5-(methylamino)pentanenitrile #,
2-(3,4-dimethoxyphenyl)-5-(methylamino)-2-propan-2-yl-pentanenitrile,
3,4-Dimethoxy-|A-[3-(methylamino)propyl]-|A-(1-methylethyl)benzeneacetonitrile,
Benzeneacetonitrile, 3,4-dimethoxy-.alpha.-[3-(methylamino)propyl]-.alpha.-(1-methylethyl)-,
m-Ethylbenzaldehyde,
UNII-L49D7PR96D,
Verapamil metabolite D-617,
L49D7PR96D,
C17H26N2O2,
CID93168,
AR-1C7118,
C17-H26-N2-O2,
D 617,
3542-36-7,